Myelofibrosis Program

About Sequantrix

Sequantrix is a Munich-based biotech startup pioneering an AI-driven approach to treat fibrosis and chronic organ diseases. The company has built a proprietary platform combining one of the world's largest human multi-modal single-cell datasets with advanced organoid assays and animal models to discover and validate novel targets. Its initial focus is on high-mortality, high-unmet-need areas including chronic kidney disease, heart failure, and myelofibrosis, with ambitions to both develop its own pipeline and partner with pharmaceutical companies. As a young, private company, it is positioned in the pre-clinical discovery and validation stage.

Therapeutic Areas

Other Myelofibrosis Drugs